1. In Vivo
  2. >>Business Strategy

Merck KGaA Health Care Head Happy With Old And New Mix

Pipeline Will Augment Established Strong Sellers

 
• By Kevin Grogan

The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.

Guenter_Peter
Peter Guenter

When Merck KGaA presented its financials for 2021 last month, it was striking to see that a number of drugs that got their first approvals last century were still making very healthy contributions to the German group's sales.

While Merck touted growth from newer products such as the multiple sclerosis tablet Mavenclad (claribine) and the checkpoint inhibitor Bavencio (avelumab), full-year sales of the type 2 diabetes mainstay Glucophage...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.